350 million people. Around 7,000 rare diseases. Some cohorts can be counted on one hand. Rebecca Stewart gives the number that changed my read: one condition has 117 known patients in the UK. Another has only three known patients globally. This is the scale problem @NiomeAI SN55 is built for. $TAO Bittensor miners can generate synthetic genomic profiles far beyond what patient recruitment can provide, giving researchers larger cohorts to study variants, drug response and disease patterns. Synthetic data still has to prove its biological value. But if NIOME gets that right, $TAO can direct intelligence toward diseases the traditional data market has little chance of serving at scale. Very bullish on this work.